Enzyme replacement therapy for Fabry disease: some answers but more questions.

Ther Clin Risk Manag · 2011 · PMC3061846 · PMID 21445281

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

of borderline significanceP =0.06so close (0.05 < p ≤ 0.1)

Although the effects of AGALB on the composite outcome were of borderline significance ( P =0.06), secondary analyses of protocol-adherent patients adjusted for baseline proteinuria demonstrated a more pronounced treatment effect compared with the placebo group ( P = 0.034).

also in 1,491 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.